Results 1 to 10 of about 4,217 (163)

Pharmacokinetics of oral moxidectin in individuals with Onchocerca volvulus infection.

open access: yesPLoS Neglected Tropical Diseases, 2022
BackgroundOnchocerciasis ("river blindness"), is a neglected tropical disease caused by the filarial nematode Onchocerca volvulus and transmitted to humans through repeated bites by infective blackflies of the genus Simulium.
Beesan Tan   +9 more
doaj   +2 more sources

Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2016
BACKGROUND:Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or ...
Beatrice Barda   +5 more
doaj   +3 more sources

Bugs and drugs: a systems biology approach to characterising the effect of moxidectin on the horse’s faecal microbiome [PDF]

open access: yesAnimal Microbiome, 2020
Background Anthelmintic treatment is a risk factor for intestinal disease in the horse, known as colic. However the mechanisms involved in the onset of disease post anthelmintic treatment are unknown.
S. P. Daniels   +3 more
doaj   +2 more sources

Analyses of emerging macrocyclic lactone resistance: Speed and signature of ivermectin and moxidectin selection and evidence of a shared genetic locus. [PDF]

open access: yesPLoS Pathogens
Subtherapeutic treatment or 'underdosing' is considered a common problem in the control of parasitic helminths of animals and people and can hasten the emergence of anthelmintic resistance.
Jennifer McIntyre   +8 more
doaj   +2 more sources

Efficacy of oral moxidectin against susceptible and resistant isolates of Dirofilaria immitis in dogs

open access: yesParasites & Vectors, 2017
Background Monthly topical and sustained-release injectable formulations of moxidectin are currently marketed; however, an oral formulation, while approved at a dose of 3 μg/kg, is not currently marketed in the United States.
Tom L. McTier   +7 more
doaj   +2 more sources

Combined high-quality metagenomics reveals off-target effects of albendazole, ivermectin-albendazole and moxidectin-albendazole on the human gut bacteria [PDF]

open access: yesnpj Biofilms and Microbiomes
Human whipworm infections caused by Trichuris trichiura and Trichuris incognita remain a major public health problem, affecting over 400 million people globally and responding poorly to standard benzimidazole chemotherapy.
Julian Dommann   +7 more
doaj   +2 more sources

Comparative efficacy of Moxidectin and Ivermectin in cattle naturally infected with old world screw worm larvae [PDF]

open access: yesIraqi Journal of Veterinary Sciences, 2005
Moxidectin is a second generation semi-synthetic Macrocyclic Lactone of the Milbemycins family, which have a broad spectrum of activity against external and internal parasite including Oestrus ovis and hypodermatosis.
E A Hassan   +3 more
doaj   +1 more source

Study of the pharmacokinetics of moxidectin in the body of carnivores using an antiparasitic drug in the form of tablets

open access: yesРоссийский паразитологический журнал, 2021
The purpose of the research is studying the pharmacokinetics of moxidectin in the blood serum of cats and dogs after a single administration of antiparasitic drug «Neoterika Protecto tablets».Materials and methods.
G. B. Arisova
doaj   +1 more source

Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs

open access: yesParasites & Vectors, 2019
Background Moxidectin has previously shown limited efficacy (≤ 44.4%) against confirmed macrocyclic lactone (ML)-resistant Dirofilaria immitis strains at 3 µg/kg after single and multiple oral dosages. Three studies were conducted to evaluate higher oral
Tom L. McTier   +7 more
doaj   +1 more source

Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs

open access: yesParasites & Vectors, 2020
Background Infection with Angiostrongylus vasorum may cause severe clinical disease, even death in dogs, however, due to the often non-specific clinical signs, diagnosis is not always straightforward. Regular prophylactic treatment may offer a safe means
Csilla Becskei   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy